Uterine Artery Embolization (UAE) is a minimally invasive procedure used to treat symptomatic uterine fibroids. The HydroPearl Microsphere (Terumo Interventional Systems) is an embolic agent approved for UAE and other embolization procedures. The purpose of this article is to describe our initial experience with HydroPearl for UAE in patients with symptomatic uterine fibroids. Twenty-one patients who underwent UAE using HydroPearl Microspheres at a single institution from May 1, 2018 to December 31, 2019 were included in the study. The electronic medical record (EMR) was reviewed for documentation of short- and long-term complications, as well as improvements in menorrhagia and bulk-type symptoms. We also describe unique attributes of the HydroPearl Microsphere that should be considered when utilizing this embolization particle for UAE. Of the 21 patients, 18 had a 3-month or later post-procedure follow-up documented in the EMR and were included in the analysis. The average time between the UAE procedure and the most recent clinical note was 145 days. Sixteen patients reported symptoms of menorrhagia and 13 reported bulk symptoms prior to the UAE procedure. On follow-up, 13/16 patients (81%) and 12/13 patients (92%) experienced improvement in menorrhagia and bulk symptoms, respectively. The only recorded complication was amenorrhea in 4 patients (22%) who had an average age of 51 years. Several characteristics of HydroPearl Microsphere may prove helpful when considering these embolic particles for use in UAE. Our initial experience with this embolic agent suggest that the reatment response for menorrhagia and bulk symptoms are largely similar to success rates reported in the literature for other embolic agents. Larger studies are needed to evaluate the safety and efficacy of this embolic particle for this indication.

中文翻译：

---

HydroPearl微球用于子宫动脉栓塞治疗有症状的子宫肌瘤的初步经验

子宫动脉栓塞术（UAE）是一种微创手术，用于治疗有症状的子宫肌瘤。HydroPearl微球（Terumo介入系统）是一种批准用于阿联酋和其他栓塞程序的栓塞剂。本文的目的是描述我们在有症状子宫肌瘤患者中使用HydroPearl治疗阿联酋的初步经验。研究纳入了2018年5月1日至2019年12月31日在单一机构使用HydroPearl微球进行阿联酋的21位患者。审查了电子病历（EMR），以记录短期和长期并发症以及月经过多和体型症状的改善。我们还描述了当将这种栓塞颗粒用于阿联酋时应考虑的HydroPearl微球的独特属性。在21例患者中，有18例在EMR中记录了3个月或更晚的术后随访，并纳入了分析。阿联酋程序与最新临床记录之间的平均时间为145天。在阿联酋手术之前，有16名患者报告了月经过多的症状，还有13名患者报告了总体症状。随访时，月经过多和本体症状分别改善了13/16例（81％）和12/13例（92％）。唯一记录的并发症是平均年龄为51岁的4名患者（22％）闭经。当考虑将这些栓塞颗粒用于阿联酋时，HydroPearl微球的一些特性可能会有所帮助。我们对该栓塞剂的初步经验表明，对月经过多和体征的退缩反应与其他栓塞剂的文献报道的成功率在很大程度上相似。需要更大的研究来评估该栓塞颗粒用于该适应症的安全性和有效性。